# Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

> **NCT05498181** · PHASE2 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Hemodialysis

## Interventions

- **DRUG:** Sacubitril-valsartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05498181
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-11
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-07-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05498181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05498181, "Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05498181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*